Senate confirms new FDA chief

Share this article:
Andrew von Eschenbach won confirmation as head of the FDA, breaking a filibuster and bolstering the agency as it heads into a period of greater legislative scrutiny. The vote was 80-11 to confirm von Eschenbach, who has been acting head of the agency for more than year. While von Eschenbach was approved in September by the Senate Health, Education, Labor and Education Committee, members of both parties had stalled a final vote on his nomination. Democrats had blocked it until the FDA decided to allow OTC sales of the Plan B emergency contraceptive pill. Von Eschenbach also faced opposition from Sen. Charles Grassley (R-Iowa), Senate Finance Committee chairman, who mounted the filibuster that was broken earlier Thursday. Grassley has been investigating the FDA’s handling of Sanofi-Aventis’ Ketek, which has been linked to severe liver problems and several deaths. Von Eschenbach has resisted release of full information about the antibiotic, saying it could have a chilling effect on the FDA’s ability to evaluate drug safety and other issues independently and objectively. The new Democratic-controlled Congress is expected to aggressively investigate several aspects of the FDA next year. Among points on the agenda are voting on reauthorization of the Prescription Drug User Fee Act.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...